QuidelOrtho (QDEL) Cash & Equivalents (2021 - 2026)

QuidelOrtho has disclosed Cash & Equivalents across 6 years of filings, most recently posting $123.4 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 18.66% year-over-year to $123.4 million; the TTM figure through Jun 2026 stood at $123.4 million (down 18.66% YoY), while the FY2025 annual figure was $169.8 million, up 72.74% from the prior year.
• Cash & Equivalents came in at $123.4 million for Q2 2026 at QuidelOrtho, down from $140.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.3 billion in Q2 2022 to a low of $79.0 million in Q1 2024.
• Average Cash & Equivalents over 5 years is $263.6 million, with a median of $149.9 million recorded in 2023.
• Year-over-year, Cash & Equivalents plunged 77.74% in 2024 and surged 72.74% in 2025.
• Over 5 years, Cash & Equivalents stood at $213.2 million in 2022, then slumped by 43.95% to $119.5 million in 2023, then fell by 17.74% to $98.3 million in 2024, then surged by 72.74% to $169.8 million in 2025, then retreated by 27.33% to $123.4 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $123.4 million in Q2 2026, $140.4 million in Q1 2026, and $169.8 million in Q4 2025.